Cart
sales@molnova.com
Trazpiroben
CAS No. 1352993-39-5
Trazpiroben( —— )
Catalog No. M35067 CAS No. 1352993-39-5
Trazpiroben (TAK-906) is a selective dopamine D2/D3 receptor antagonist utilized in gastroparesis research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTrazpiroben
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrazpiroben (TAK-906) is a selective dopamine D2/D3 receptor antagonist utilized in gastroparesis research.
-
DescriptionTrazpiroben (TAK-906) is a dopamine D2/D3 receptor antagonist used for chronic research of moderate-to-severe gastroparesis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1352993-39-5
-
Formula Weight517.66
-
Molecular FormulaC31H39N3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)C1=CC=CC(=C1)CN2C(=O)C3(N(C2)C4CCCCC4)CCN(CCCC(=O)C=5C=CC=CC5)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kuo B, Scimia C, Dukes G, Zhang W, Gupta S, Chen C, Chuang E, Camilleri M. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2?/D3?receptor antagonist, in patients with gastroparesis. Aliment Ph?
molnova catalog
related products
-
Xaliproden hydrochlo...
Xaliproden is a compound that mimics the effects of nerve growth factor and is also a serotonin 5-HT1A receptor agonist.
-
PNU-96391
PNU-96391 is an antagonist of dopamine D2 and a partial agonist of 5-HT2A. PNU-96391 can be used in research on the treatment of chronic diseases.
-
ONC206
ONC206 is an analogue of TRAIL inducer ONC201 and is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 also has broad-spectrum anti-tumor activity. ONC206 (Oncoceutics) is an imipiridone with nanomolar potency and analogue of ONC201, a selective dopamine receptor D2 (DRD2) antagonist currently being investigated in phase II clinical trials for serous endometrial cancer (SEC).??
